

## SUPPLEMENTARY MATERIAL

**Table S1.** Tumor characteristics at initial diagnosis.


No. T grade (%)	
1	5 (19.2)
2	5 (19.2)
3	15 (57.7)
4	1 (3.8)
No. T stage (%)	
1	5, T1a 4, T1b 1
2	5, T2a 4, T2b 1
3	15, T3a 13, T3b 2
4	1
No. pN category (%)	
N+	2 (7.7)
Nx	3 (11.5)
No. clinical M category (%)	
M0	4 (15.4)
M1 synchronic	5 (19.2)
M1 metachronic	16 (61.5)

**Table S2.** Site and uptake (SUVmax) of the target lesion in the enrolled patients with positive PSMA-PET.

Patient	Site of the target lesion	SUVmax
1	Liver (S2)	48.36
2	Left sacrum	46.37
3	Mediastinal node	35.44
4	Lumbar-aortic mass	66.6
5	Renal fossa	114.57
6	Sacrum	24.03
7	Ilium	10.2
8	Right adrenal gland	9.63
9	Renal fossa	7.4
10	Lung parenchima	7.4
11	Lung parenchima	8.17
12	Lung parenchima	24.94

13	Right kidney	9.96
14	Right kidney	54.25
15	Left kidney	5.45
		5.45

Patient	Site of the target lesion	SUVmax
1	Liver (S2)	48.36
2	Left sacrum	46.37
3	Mediastinal node	35.44
4	Lumbar-aortic mass	66.6
5	Renal fossa	114.57
6	Sacrum	24.03
7	Ilium	10.2
8	Right adrenal gland	9.63
9	Renal fossa	7.4
10	Lung parenchima	7.4
11	Lung parenchima	8.17
12	Lung parenchima	24.94
13	Right kidney	9.96
14	Right kidney	54.25
15	Left kidney	5.45
		5.45



**Figure S1.** Behavior of SUVmax and TBR of the target lesion in subjects with positive PSMA-PET/CT